Thu Oct 30 12:59:15 UTC 2025: Here’s a summary of the text and a rewritten version as a news article:
Summary:
Despite President Trump’s earlier warnings and a recent lawsuit from Texas, U.S. Health Secretary Robert F. Kennedy Jr. stated that while evidence doesn’t definitively prove Tylenol causes autism, its use should still be approached with caution during pregnancy. This follows concerns raised about a potential link between Tylenol use during pregnancy and autism, prompting Kenvue, the maker of Tylenol, to defend its product and reaffirm the lack of a proven scientific connection. The company maintains that women should consult with their doctors before using Tylenol during pregnancy and has asked the FDA to reject calls for autism warning labels. The news has impacted Kenvue’s stock price.
News Article:
Tylenol-Autism Link Remains Unproven, Says Health Secretary, Despite Ongoing Debate
Washington D.C. – October 30, 2025 – In a move that adds further nuance to an already heated debate, U.S. Health Secretary Robert F. Kennedy Jr. addressed the ongoing concerns surrounding a potential link between the pain reliever Tylenol (acetaminophen) and autism. While acknowledging suggestive evidence from animal and observational studies, Kennedy stated that current evidence doesn’t definitively prove a causative relationship.
“The causative association between Tylenol given in pregnancy and the perinatal periods is not sufficient to say it definitely causes autism. But it is very suggestive,” Secretary Kennedy told reporters Wednesday. “There should be a cautious approach to it.”
His statement comes a month after President Trump cautioned pregnant women against using the medication, a claim made without citing specific scientific evidence. It also follows a lawsuit filed by the state of Texas against Kenvue, the manufacturer of Tylenol.
Kenvue, spun off from Johnson & Johnson in 2023, has repeatedly defended its product, issuing a statement emphasizing the absence of a proven scientific connection to autism. “We agree, as Secretary Kennedy said, that the best message to pregnant women is to consult their healthcare professional before taking acetaminophen, which is what our Tylenol label tells consumers to do. We also agree that there is no definitive causative association between taking acetaminophen and autism,” the company said. Kenvue has urged the FDA to reject calls for an autism warning label.
The controversy continues to impact Kenvue’s market performance. The company’s shares closed down 1.4% on Wednesday.
The debate surrounding Tylenol’s safety during pregnancy highlights the challenges of interpreting complex scientific data and the far-reaching implications of public health messaging. The situation is still developing, and both medical professionals and the FDA will continue to scrutinize the available evidence.
First Piper 